Literature DB >> 11481463

Progress in cancer vaccines by enhanced self-presentation.

S R Riddell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11481463      PMCID： PMC55350          DOI： 10.1073/pnas.171326398

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  47 in total

1.  Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity.

Authors:  D J Morgan; H T Kreuwel; S Fleck; H I Levitsky; D M Pardoll; L A Sherman
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

Review 2.  Dendritic cells and the control of immunity.

Authors:  J Banchereau; R M Steinman
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

3.  The duration of antigenic stimulation determines the fate of naive and effector T cells.

Authors:  G Iezzi; K Karjalainen; A Lanzavecchia
Journal:  Immunity       Date:  1998-01       Impact factor: 31.745

4.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

5.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.

Authors:  K Staveley-O'Carroll; E Sotomayor; J Montgomery; I Borrello; L Hwang; S Fein; D Pardoll; H Levitsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

6.  Flt3 ligand induces tumor regression and antitumor immune responses in vivo.

Authors:  D H Lynch; A Andreasen; E Maraskovsky; J Whitmore; R E Miller; J C Schuh
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

7.  Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.

Authors:  F O Nestle; S Alijagic; M Gilliet; Y Sun; S Grabbe; R Dummer; G Burg; D Schadendorf
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

Review 8.  Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens.

Authors:  W R Heath; C Kurts; J F Miller; F R Carbone
Journal:  J Exp Med       Date:  1998-05-18       Impact factor: 14.307

9.  Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites.

Authors:  M C Dieu; B Vanbervliet; A Vicari; J M Bridon; E Oldham; S Aït-Yahia; F Brière; A Zlotnik; S Lebecque; C Caux
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

10.  Heteroclitic immunization induces tumor immunity.

Authors:  R Dyall; W B Bowne; L W Weber; J LeMaoult; P Szabo; Y Moroi; G Piskun; J J Lewis; A N Houghton; J Nikolić-Zugić
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.